SYT10

Across TCGA pan-cancer cohorts, SYT10 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SYT10 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher SYT10 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SYT10 expression acts as an unfavorable survival marker, although some lineages such as LUAD and SKCM show a favorable association.

ACC, LIHC, and ESCA are the cancer types where SYT10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.273	0.802	.017	15	view →
LIHC	DFS	Median	All	0.090	0.555	.001	15	view →
ESCA	OS	Median	All	0.080	0.701	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	OS	Median	IV	0.188	0.481	.046	3	view →
LUAD	DFS	Median	All	1.000	0.333	.044	3	view →
SKCM	DFS	Median	IV	1.000	0.201	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SYT10–ACC (OS)

Open the ACC breakdown →